Anti-CSF2/ CSF/ GMCSF monoclonal antibody

Anti-CSF2/ CSF/ GMCSF antibody for FACS & in-vivo assay

Target products collectionGo to CSF2/CSF2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T74002-Ab-1/ GM-Tg-hg-T74002-Ab-2Anti-Human CSF2 monoclonal antibodyHuman
GM-Tg-rg-T74002-Ab-1/ GM-Tg-rg-T74002-Ab-2Anti-Rat CSF2 monoclonal antibodyRat
GM-Tg-mg-T74002-Ab-1/ GM-Tg-mg-T74002-Ab-2Anti-Mouse CSF2 monoclonal antibodyMouse
GM-Tg-cynog-T74002-Ab-1/ GM-Tg-cynog-T74002-Ab-2Anti-Cynomolgus/ Rhesus macaque CSF2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T74002-Ab-1/ GM-Tg-felg-T74002-Ab-2Anti-Feline CSF2 monoclonal antibodyFeline
GM-Tg-cang-T74002-Ab-1/ GM-Tg-cang-T74002-Ab-2Anti-Canine CSF2 monoclonal antibodyCanine
GM-Tg-bovg-T74002-Ab-1/ GM-Tg-bovg-T74002-Ab-2Anti-Bovine CSF2 monoclonal antibodyBovine
GM-Tg-equg-T74002-Ab-1/ GM-Tg-equg-T74002-Ab-2Anti-Equine CSF2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T74002-Ab-1/ GM-Tg-hg-T74002-Ab-2; GM-Tg-rg-T74002-Ab-1/ GM-Tg-rg-T74002-Ab-2;
GM-Tg-mg-T74002-Ab-1/ GM-Tg-mg-T74002-Ab-2; GM-Tg-cynog-T74002-Ab-1/ GM-Tg-cynog-T74002-Ab-2;
GM-Tg-felg-T74002-Ab-1/ GM-Tg-felg-T74002-Ab-2; GM-Tg-cang-T74002-Ab-1/ GM-Tg-cang-T74002-Ab-2;
GM-Tg-bovg-T74002-Ab-1/ GM-Tg-bovg-T74002-Ab-2; GM-Tg-equg-T74002-Ab-1/ GM-Tg-equg-T74002-Ab-2
Products NameAnti-CSF2 monoclonal antibody
Formatmab
Target NameCSF2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CSF2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-303Pre-Made Lenzilumab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody
    BiosimilarGMP-Bios-ab-244Pre-Made Gimsilumab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody
    BiosimilarGMP-Bios-ab-453Pre-Made Plonmarlimab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody
    BiosimilarGMP-Bios-ab-362Pre-Made Namilumab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody
    BiosimilarGMP-Bios-ab-415Pre-Made Otilimab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody
    Target AntigenProducts DevelopingMulti-species CSF2/ CSF/ GMCSF VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMLP000211human CSF2 Lentivirus particle
    ORF Viral VectorpGMLP000211human CSF2 Lentivirus plasmid
    ORF Viral VectorpGMAAV000364human CSF2 AAV plasmid
    ORF Viral VectorvGMAAV000364human CSF2 AAV particle
    ORF Viral VectorpGMLPm001883mouse Csf2 Lentivirus plasmid
    ORF Viral VectorvGMLPm001883mouse Csf2 Lentivirus particle


    Target information

    Target IDGM-T74002
    Target NameCSF2
    Gene ID1437,12981,116630,574371,403923,101094153,281095,100033981
    Gene Symbol and SynonymsCSF,CSF2,Csfgm,Gm-CSf,GMCSF,MGI-IGM
    Uniprot AccessionP04141,P48750,P48749,P11052
    Uniprot Entry NameCSF2_HUMAN,CSF2_RAT,CSF2_CANLF,CSF2_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index
    Diseasemetastatic tumors, Overactive bladder
    Gene EnsemblENSG00000164400
    Target ClassificationCheckpoint-Immuno Oncology

    The target: CSF2, gene name: CSF2, also named as CSF, GMCSF. The protein encoded by this gene is a cytokine that controls the production, differentiation, and function of granulocytes and macrophages. The active form of the protein is found extracellularly as a homodimer. This gene has been localized to a cluster of related genes at chromosome region 5q31, which is known to be associated with interstitial deletions in the 5q- syndrome and acute myelogenous leukemia. Other genes in the cluster include those encoding interleukins 4, 5, and 13. This gene plays a role in promoting tissue inflammation. Elevated levels of cytokines, including the one produced by this gene, have been detected in SARS-CoV-2 infected patients that develop acute respiratory distress syndrome. Mice deficient in this gene or its receptor develop pulmonary alveolar proteinosis. [provided by RefSeq, Aug 2020].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.